Skip to main content

Advertisement

SpringerLink
Log in

Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics

  • Review
  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Despite the advent of highly active antiretroviral therapy (HAART), HIV-associated neurological disorders (HAND) remain a major challenge in human immunodeficiency virus (HIV) treatment. The early implementation of HAART in the infected individuals helps suppress the viral replication in the plasma and other compartments. Several studies also report the beneficial effect of drugs that successfully penetrate central nervous system (CNS). However, recent data in both clinical setup and in in vitro studies indicate CNS toxicity of the antiretrovirals (ARVs). Although the evidence is limited, correlation between prolonged use of ARVs and neurotoxicity strongly suggests that it is essential to study the underlying mechanisms responsible for such toxicity. Furthermore, closer attention toward clinical outcomes is required to screen various ARV regimens for their association with HAND and other comorbidities. A growing body of literature also indicates a possible role of accelerated aging in the antiretroviral therapy-associated neurotoxicity. Lastly, owing to high pill burden, multiple drugs in the HIV treatment also invite a possible role of drug–drug interaction via various cytochrome P450 enzymes. The particular emphasis of this review is to highlight the need to identify alternative approaches in reducing the CNS toxicity of the ARV drugs in HIV-infected individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis 37:13–25

    Article  CAS  PubMed  Google Scholar 

  • Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ (2008) Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65(Suppl 1):38–46. doi:10.1111/j.1365-2125.2008.03134.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Abers MS, Shandera WX, Kass JS (2013) Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 28:131–145. doi:10.1007/s40263-013-0132-4

    Article  CAS  Google Scholar 

  • AIDS by the numbers 2015 (2015) http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf. Accessed 8 April 2016

  • Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, Gannon PJ, Mankowski J, Dorsey JL, Buch AM, Cross SA, Cook DR, Pena MM, Andersen ES, Christofidou-Solomidou M, Lindl KA, Zink MC, Clements J, Pierce RC, Kolson DL, Jordan-Sciutto KL (2014) Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 20:39–53. doi:10.1007/s13365-013-0227-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • András IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 74:255–265

    Article  PubMed  CAS  Google Scholar 

  • András IE, Pu H, Tian J, Deli MA, Nath A, Hennig B, Toborek M (2005) Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 25:1159–1170

    Article  PubMed  CAS  Google Scholar 

  • András IE, Toborek M (2011) HIV-1-induced alterations of claudin-5 expression at the blood–brain barrier level. Methods Mol Biol 762:355–370

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111:529–538. doi:10.1007/s00401-006-0037-0

    Article  CAS  PubMed  Google Scholar 

  • Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Antiretroviral Therapy Cohort C (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293–299. doi:10.1016/S0140-6736(08)61113-7

    Article  Google Scholar 

  • Apostolova N, Funes HA, Blas-Garcia A, Alegre F, Polo M, Esplugues JV (2015) Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells. J Infect Dis 211:1953–1958. doi:10.1093/infdis/jiu825

    Article  PubMed  Google Scholar 

  • Atluri VSR, Hidalgo M, Samikkannu T, Kurapati KRV, Jayant RD, Sagar V, Nair MP (2015) Effect of human immunodeficiency virus on blood–brain barrier integrity and function: an update. Front Cell Neurosci 9:212

    Article  PubMed  PubMed Central  Google Scholar 

  • Auclair M, Afonso P, Capel E, Caron-Debarle M, Capeau J (2014) Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir Ther 19:773–782

    Article  CAS  PubMed  Google Scholar 

  • Azzam R, Lal L, Goh SL, Kedzierska K, Jaworowski A, Naim E, Cherry CL, Wesselingh SL, Mills J, Crowe SM (2006) Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J Acquir Immune Defic Syndr 42:19–28. doi:10.1097/01.qai.0000214809.83218.88

    CAS  PubMed  Google Scholar 

  • Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA (2004) Vascular endothelial toxicity induced by HIV protease inhibitor. Cardiovasc Toxicol 4:199–206

    Article  CAS  PubMed  Google Scholar 

  • Ballabh P, Braun A, Nedergaard M (2004) The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16:1–13

    Article  CAS  PubMed  Google Scholar 

  • Banks WA, Erickson MA (2010) The blood–brain barrier and immune function and dysfunction. Neurobiol Dis 37:26–32

    Article  CAS  PubMed  Google Scholar 

  • Bazzoni G, Dejana E (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84:869–901

    Article  CAS  PubMed  Google Scholar 

  • Becker JT, Lopez OL, Dew MA, Aizenstein HJ (2004) Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18(Suppl 1):S11–S18

    Article  PubMed  Google Scholar 

  • Bertrand L, Toborek M (2015) Dysregulation of endoplasmic reticulum stress and autophagic responses by the antiretroviral drug efavirenz. Mol Pharmacol 88:304–315. doi:10.1124/mol.115.098590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Blas-Garcia A, Polo M, Alegre F, Funes HA, Martinez E, Apostolova N, Esplugues JV (2014) Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. J Antimicrob Chemother 69:2995–3000. doi:10.1093/jac/dku262

    Article  CAS  PubMed  Google Scholar 

  • Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T (2000) Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 23:236–245

    Article  CAS  PubMed  Google Scholar 

  • Borjabad A, Morgello S, Chao W, Kim SY, Brooks AI, Murray J, Potash MJ, Volsky DJ (2011) Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog 7:e1002213. doi:10.1371/journal.ppat.1002213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bressani RF, Nowacek AS, Singh S, Balkundi S, Rabinow B, McMillan J, Gendelman HE, Kanmogne GD (2011) Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology 5:592–605. doi:10.3109/17435390.2010.541292

    Article  CAS  PubMed  Google Scholar 

  • Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G (2009) Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 4:163–174. doi:10.1007/s11481-008-9143-1

    Article  PubMed  Google Scholar 

  • Brown KC, Paul S, Kashuba AD (2009) Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 48:211–241. doi:10.2165/00003088-200948040-00001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, Tan J, Giunta B (2014) Efavirenz promotes beta-secretase expression and increased Abeta1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One 9:e95500. doi:10.1371/journal.pone.0095500

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bumpus NN, Kent UM, Hollenberg PF (2006) Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 318:345–351. doi:10.1124/jpet.106.102525

    Article  CAS  PubMed  Google Scholar 

  • Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernan MA, Collaboration H-C (2014) Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 83:134–141. doi:10.1212/WNL.0000000000000564

    Article  PubMed  PubMed Central  Google Scholar 

  • Carroll-Anzinger D, Al-Harthi L (2006) Gamma interferon primes productive human immunodeficiency virus infection in astrocytes. J Virol 80:541–544. doi:10.1128/JVI.80.1.541-544.2006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carvalhal A, Gill MJ, Letendre SL, Rachlis A, Bekele T, Raboud J, Burchell A, Rourke SB, the Centre for Brain Health in HA (2015) Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. J Neurovirol. doi:10.1007/s13365-015-0404-5

    PubMed  Google Scholar 

  • Cassol E, Misra V, Dutta A, Morgello S, Gabuzda D (2014) Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS 28:1579–1591. doi:10.1097/QAD.0000000000000303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cespedes MS, Aberg JA (2006) Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29:865–874

    Article  CAS  PubMed  Google Scholar 

  • Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD (2008) STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood–brain barrier. Blood 111:2062–2072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen C, Lu X-H, Yan S, Chai H, Yao Q (2005) HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun 335:874–882

    Article  CAS  PubMed  Google Scholar 

  • Cherry CL, Duncan AJ, Mackie KF, Wesselingh SL, Brew BJ (2008) A report on the effect of commencing enfuvirtide on peripheral neuropathy. AIDS Res Hum Retrovir 24:1027–1030. doi:10.1089/aid.2007.0300

    Article  CAS  PubMed  Google Scholar 

  • Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ (2010) Ubisol-AquaTM: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model. CHR 8:232–239. doi:10.2174/157016210791111106

    Article  CAS  Google Scholar 

  • Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25:F7–12. doi:10.1097/QAD.0b013e328345766f

    Article  CAS  PubMed  Google Scholar 

  • Cysique LA, Brew BJ (2009) Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 19:169–185. doi:10.1007/s11065-009-9092-3

    Article  PubMed  Google Scholar 

  • Dalakas MC, Semino-Mora C, Leon-Monzon M (2001) Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Investig 81:1537–1544

    Article  CAS  PubMed  Google Scholar 

  • Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149–173. doi:10.1146/annurev.pharmtox.43.100901.140251

    Article  CAS  PubMed  Google Scholar 

  • Divi RL, Einem TL, Fletcher SL, Shockley ME, Kuo MM, St Claire MC, Cook A, Nagashima K, Harbaugh SW, Harbaugh JW, Poirier MC (2010) Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci 118:191–201. doi:10.1093/toxsci/kfq235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dragovic G, Jevtovic D (2003) Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother 14:281–284

    Article  CAS  PubMed  Google Scholar 

  • Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, Cusini A, Gunthard HF, Cavassini M, Vernazza PL, Swiss HIVCS (2013) Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 27:203–210. doi:10.1097/QAD.0b013e32835a9a4a

    Article  PubMed  CAS  Google Scholar 

  • Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190–194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eagling VA, Wiltshire H, Whitcombe IW, Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1–17

    Article  CAS  PubMed  Google Scholar 

  • Eisfeld C, Reichelt D, Evers S, Husstedt I (2012) CSF penetration by antiretroviral drugs. CNS Drugs 27:31–55. doi:10.1007/s40263-012-0018-x

    Article  CAS  Google Scholar 

  • Eisfeld C, Reichelt D, Evers S, Husstedt I (2013) CSF penetration by antiretroviral drugs. CNS Drugs 27:31–55. doi:10.1007/s40263-012-0018-x

    Article  CAS  PubMed  Google Scholar 

  • Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, Simpson DM, Ake C, Collier AC, Gelman BB, McCutchan JA, Morgello S, Grant I, Group C (2008) Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 64:566–572. doi:10.1002/ana.21484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eugenin EA, Clements JE, Zink MC, Berman JW (2011) Human immunodeficiency virus infection of human astrocytes disrupts blood–brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 31:9456–9465. doi:10.1523/JNEUROSCI.1460-11.2011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet AM, Group AS (2013) Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Chemother 57:2154–2160. doi:10.1128/AAC.02294-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ferrari LF, Levine JD (2010) Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. Eur J Neurosci 32:811–818. doi:10.1111/j.1460-9568.2010.07355.x

    Article  PubMed  PubMed Central  Google Scholar 

  • Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, Cashman J, Buga G, Byrns RE, Barbaro G (2004) HAART drugs induce mitochondrial damage and intercellular gaps and gp 120 causes apoptosis. Cardiovasc Toxicol 4:327–337

    Article  CAS  PubMed  Google Scholar 

  • Fu W, Chai H, Yao Q, Chen C (2005) Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression JAIDS. J Acquir Immune Defic Syndr 39:152–158

    CAS  PubMed  Google Scholar 

  • Fumaz CR, Gonzalez-Garcia M, Borras X, Munoz-Moreno JA, Perez-Alvarez N, Mothe B, Brander C, Ferrer MJ, Puig J, Llano A, Fernandez-Castro J, Clotet B (2012) Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. Brain Behav Immun 26:568–572. doi:10.1016/j.bbi.2012.01.001

    Article  CAS  PubMed  Google Scholar 

  • Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N (2015) Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. J Antimicrob Chemother 70:2249–2254. doi:10.1093/jac/dkv098

    Article  CAS  PubMed  Google Scholar 

  • Fung HB, Guo Y (2004) Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352–378

    Article  CAS  PubMed  Google Scholar 

  • Galluzzi L, Pinti M, Troiano L, Prada N, Nasi M, Ferraresi R, Salomoni P, Mussini C, Cossarizza A (2005) Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 10:191–195

    CAS  PubMed  Google Scholar 

  • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, study UKCHC (2011) Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 76:693–700. doi:10.1212/WNL.0b013e31820d8b0b

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis 45:1230–1237. doi:10.1086/522175

    Article  CAS  PubMed  Google Scholar 

  • Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306

    Article  CAS  PubMed  Google Scholar 

  • Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD (2011) Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4:23. doi:10.1186/1756-6606-4-23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Glover M, Hebert VY, Nichols K, Xue SY, Thibeaux TM, Zavecz JA, Dugas TR (2014) Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT-or 3TC-induced endothelial dysfunction. Antivir Res 111:136–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gomes MJ, Neves J, Sarmento B (2014) Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed 9:1757–1769

    Google Scholar 

  • Gongvatana A, Harezlak J, Buchthal S, Daar E, Schifitto G, Campbell T, Taylor M, Singer E, Algers J, Zhong J, Brown M, McMahon D, So YT, Mi D, Heaton R, Robertson K, Yiannoutsos C, Cohen RA, Navia B, Consortium HIVN (2013) Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol 19:209–218. doi:10.1007/s13365-013-0162-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Govindarajan R, Leung GP, Zhou M, Tse C-M, Wang J, Unadkat JD (2009) Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 296:G910–G922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79–85. doi:10.1111/j.1742-7843.2006.pto_249.x

    Article  CAS  PubMed  Google Scholar 

  • Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19:407–411

    Article  CAS  PubMed  Google Scholar 

  • Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD (2008) Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. BMC Neurosci 9:27

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Grund B, Wright EJ, Brew BJ, Price RW, Roediger MP, Bain MP, Hoy JF, Shlay JC, Vjecha MJ, Robertson KR, Group ISS (2013) Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. J Neurovirol 19:383–392. doi:10.1007/s13365-013-0190-x

    Article  PubMed  PubMed Central  Google Scholar 

  • Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (2016) https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 13 March 2016

  • Gupta S, Knight AG, Losso BY, Ingram DK, Keller JN, Bruce-Keller AJ (2012) Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. Antivir Res 95:19–29. doi:10.1016/j.antiviral.2012.04.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hagler DN, Frame PT (1986) Azidothymidine neurotoxicity. Lancet 2:1392–1393

    Article  CAS  PubMed  Google Scholar 

  • Harris M, Larsen G, Montaner JS (2008) Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 22:1890–1892. doi:10.1097/QAD.0b013e32830e0169

    Article  PubMed  Google Scholar 

  • Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H (2013) Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun 439:221–227

    Article  CAS  PubMed  Google Scholar 

  • Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096. doi:10.1212/WNL.0b013e318200d727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I, Group C (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60:473–480. doi:10.1093/cid/ciu862

    Article  PubMed  Google Scholar 

  • Huang W, Eum SY, András IE, Hennig B, Toborek M (2009) PPARα and PPARγ attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 23:1596–1606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hyland R, Dickins M, Collins C, Jones H, Jones B (2008) Maraviroc: in vitro assessment of drug–drug interaction potential. Br J Clin Pharmacol 66:498–507. doi:10.1111/j.1365-2125.2008.03198.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193–200. doi:10.1016/j.tips.2004.02.007

    Article  CAS  PubMed  Google Scholar 

  • Jamaluddin MS, Lin PH, Yao Q, Chen C (2010) Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis 208:104–111

    Article  CAS  PubMed  Google Scholar 

  • James CW, McNelis KC, Matalia MD, Cohen DM, Szabo S (2002) Central nervous system toxicity and amprenavir oral solution. Ann Pharmacother 36:174

    Article  PubMed  Google Scholar 

  • Jensen BK, Monnerie H, Mannell MV, Gannon PJ, Espinoza CA, Erickson MA, Bruce-Keller AJ, Gelman BB, Briand LA, Pierce RC, Jordan-Sciutto KL, Grinspan JB (2015) Altered oligodendrocyte maturation and myelin maintenance: the role of antiretrovirals in HIV-associated neurocognitive disorders. J Neuropathol Exp Neurol 74:1093–1118. doi:10.1097/NEN.0000000000000255

    Article  CAS  PubMed  Google Scholar 

  • Jin J, Grimmig B, Izzo J, Brown LA, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B (2016) HIV non-nucleoside reverse transcriptase inhibitor efavirenz reduces neural stem cell proliferation in vitro and in vivo. Cell Transplant. doi:10.3727/096368916X691457

    PubMed  Google Scholar 

  • Kakuda TN, Scholler-Gyure M, Hoetelmans RM (2010) Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 15:817–829. doi:10.3851/IMP1652

    Article  CAS  PubMed  Google Scholar 

  • Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y (2007) HIV-1 gp120 compromises blood–brain barrier integrity and enhance monocyte migration across blood–brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 27:123–134

    Article  CAS  PubMed  Google Scholar 

  • Kaul M (2008) HIV’s double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci 13:2484–2494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988–994. doi:10.1038/35073667

    Article  CAS  PubMed  Google Scholar 

  • Kelly SG, Taiwo BO, Wu Y, Bhatia R, Kettering CS, Gao Y, Li S, Hutten R, Ragin AB (2014) Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum. J Neurovirol 20:514–520. doi:10.1007/s13365-014-0261-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654–660

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kis O, Robillard K, Chan GN, Bendayan R (2010) The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22–35

    Article  CAS  PubMed  Google Scholar 

  • Kline ER, Sutliff RL (2008) The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 56:752–769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kline ER, Bassit L, Hernandez-Santiago BI, Detorio MA, Liang B, Kleinhenz DJ, Walp ER, Dikalov S, Jones DP, Schinazi RF (2009) Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. Cardiovasc Toxicol 9:1–12

    Article  CAS  PubMed  Google Scholar 

  • Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R (2005) Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111:194–213. doi:10.1016/j.virusres.2005.04.009

    Article  PubMed  CAS  Google Scholar 

  • Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423–431

    CAS  PubMed  Google Scholar 

  • Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug–drug interaction. Drug Metab Dispos 27:902–908

    CAS  PubMed  Google Scholar 

  • Lai EC (2002) Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins. EMBO Rep 3:840–845

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lai Y, Tse CM, Unadkat JD (2004) Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 279:4490–4497. doi:10.1074/jbc.M307938200

    Article  CAS  PubMed  Google Scholar 

  • Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, Group TS (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–2185. doi:10.1056/NEJMoa035026

    Article  CAS  PubMed  Google Scholar 

  • Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, Group TS (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186–2195. doi:10.1056/NEJMoa035211

    Article  CAS  PubMed  Google Scholar 

  • Lee H, Hanes J, Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711–14719. doi:10.1021/bi035596s

    Article  CAS  PubMed  Google Scholar 

  • Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137–142

    PubMed  PubMed Central  Google Scholar 

  • Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45–55

    PubMed  Google Scholar 

  • Lewis W (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antivir Res 58:189–197

    Article  CAS  PubMed  Google Scholar 

  • Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609–616

    CAS  PubMed  Google Scholar 

  • Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C (2012) Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J Neurochem 120:106–114. doi:10.1111/j.1471-4159.2011.07549.x

    Article  CAS  PubMed  Google Scholar 

  • Liu Z-J, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23:14–25

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Liu H, Liu Z, Yang X, Huang F, Ma C, Li Z (2008) Neurotoxicity caused by didanosine on cultured dorsal root ganglion neurons. Cell Biol Toxicol 24:113–121. doi:10.1007/s10565-007-9021-2

    Article  CAS  PubMed  Google Scholar 

  • Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL, Group C (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170–178. doi:10.1007/s13365-015-0382-7

    Article  CAS  PubMed  Google Scholar 

  • Mahajan SD, Roy I, Xu G, Yong KT, Ding H, Aalinkeel R, Reynolds J, Sykes D, Nair BB, Lin EY, Prasad PN, Schwartz SA (2010) Enhancing the delivery of anti retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles. Curr HIV Res 8:396–404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mahringer A, Fricker G (2016) ABC transporters at the blood–brain barrier. Expert Opin Drug Metab Toxicol 12:499–508. doi:10.1517/17425255.2016.1168804

    Article  CAS  PubMed  Google Scholar 

  • Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147–169

    Article  CAS  PubMed  Google Scholar 

  • Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR (2010) Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood–brain barrier integrity. J Neurochem 115:515–525

    Article  CAS  PubMed  Google Scholar 

  • Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood–brain barrier endothelial cells. Free Radic Biol Med 50:801–810

    Article  CAS  PubMed  Google Scholar 

  • Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, Team ACTGS (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366. doi:10.1097/QAD.0b013e32832c4152

    Article  PubMed  PubMed Central  Google Scholar 

  • Maxwell S, Scheftner WA, Kessler HA, Busch K (1988) Manic syndrome associated with zidovudine treatment. JAMA 259:3406–3407

    Article  CAS  PubMed  Google Scholar 

  • Meyer RP, Gehlhaus M, Knoth R, Volk B (2007) Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 8:297–306

    Article  CAS  PubMed  Google Scholar 

  • Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA (2012) The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64:803–833. doi:10.1124/pr.111.005553

    Article  CAS  PubMed  Google Scholar 

  • Mondal D, Pradhan L, Ali M, Agrawal KC (2004) HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells. Cardiovasc Toxicol 4:287–302

    Article  CAS  PubMed  Google Scholar 

  • Morlese JF, Qazi NA, Gazzard BG, Nelson MR (2002) Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS 16:1840–1841

    Article  PubMed  Google Scholar 

  • Nag S, Kapadia A, Stewart D (2011) Review: molecular pathogenesis of blood–brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 37:3–23

    Article  CAS  PubMed  Google Scholar 

  • Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24:8813–8822

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Mahony SM, Myint AM, Steinbusch H, Leonard BE (2005) Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. NeuroImmunoModulation 12:293–298. doi:10.1159/000087107

    Article  PubMed  CAS  Google Scholar 

  • Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879–3884. doi:10.1073/pnas.0800050105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pedrol E, Llibre JM, Tasias M, Curran A, Guardiola JM, Deig E, Guelar A, Martinez-Madrid O, Tikhomirova L, Ramirez R, Group RS (2015) Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med 16:628–634. doi:10.1111/hiv.12298

    Article  CAS  PubMed  Google Scholar 

  • Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR (2011) Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother 66:1954–1962. doi:10.1093/jac/dkr229

    Article  CAS  PubMed  Google Scholar 

  • Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223–236

    Article  PubMed  Google Scholar 

  • Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M (2014) Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry 19:733–741. doi:10.1038/mp.2013.89

    Article  CAS  PubMed  Google Scholar 

  • Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, Gill MJ, Power C (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59:816–824. doi:10.1002/ana.20816

    Article  CAS  PubMed  Google Scholar 

  • Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 12:295–312

    Article  CAS  PubMed  Google Scholar 

  • Purnell PR, Fox HS (2014) Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther 351:250–258. doi:10.1124/jpet.114.217869

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR (2004) Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 25:195–200

    PubMed  PubMed Central  Google Scholar 

  • Ramanathan S, Mathias AA, German P, Kearney BP (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50:229–244. doi:10.2165/11584570-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  • Renn CL, Leitch CC, Lessans S, Rhee P, McGuire WC, Smith BA, Traub RJ, Dorsey SG (2011) Brain-derived neurotrophic factor modulates antiretroviral-induced mechanical allodynia in the mouse. J Neurosci Res 89:1551–1565. doi:10.1002/jnr.22685

    Article  CAS  PubMed  Google Scholar 

  • Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR (2008) Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 49:513–519. doi:10.1097/QAI.0b013e318183a425

    Article  CAS  PubMed  Google Scholar 

  • Robertson K, Su Z, Margolis D, Krambrink A, Havlir D, Evans S, Skiest D, Team AS (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74:1260–1266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18:388–399. doi:10.1007/s13365-012-0120-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robinson B, Li Z, Nath A (2007) Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J Neurovirol 13:160–167. doi:10.1080/13550280701200102

    Article  CAS  PubMed  Google Scholar 

  • Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A, Swiss HIVCS (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15:1–5

    Article  CAS  PubMed  Google Scholar 

  • Rumbaugh JA, Nath A (2006) Developments in HIV neuropathogenesis. Curr Pharm Des 12:1023–1044

    Article  CAS  PubMed  Google Scholar 

  • Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142. doi:10.1080/13550280290049615

    Article  PubMed  CAS  Google Scholar 

  • Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285–289. doi:10.1097/QAI.0b013e3181bf648a

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sanchez Martin A, Cabrera Figueroa S, Cruz Guerrero R, Hurtado LP, Hurle AD, Carracedo Alvarez A (2013) Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics 14:1167–1178. doi:10.2217/pgs.13.111

    Article  CAS  PubMed  Google Scholar 

  • Sanchez AB, Varano GP, de Rozieres CM, Maung R, Catalan IC, Dowling CC, Sejbuk NE, Hoefer MM, Kaul M (2016) Antiretrovirals, methamphetamine, and HIV-1 envelope protein gp120 compromise neuronal energy homeostasis in association with various degrees of synaptic and neuritic damage. Antimicrob Agents Chemother 60:168–179. doi:10.1128/AAC.01632-15

    Article  CAS  Google Scholar 

  • Saracchini S, Vaccher E, Covezzi E, Tortorici G, Carbone A, Tirelli U (1989) Lethal neurotoxicity associated to azidothymidine therapy. J Neurol Neurosurg Psychiatry 52:544–545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schaerf FW, Miller R, Pearlson GD, Kaminsky MJ, Weaver D (1988) Manic syndrome associated with zidovudine. JAMA 260:3587–3588. doi:10.1001/jama.1988.03410240045016

    Article  Google Scholar 

  • Seider TR, Luo X, Gongvatana A, Devlin KN, de la Monte SM, Chasman JD, Yan P, Tashima KT, Navia B, Cohen RA (2014) Verbal memory declines more rapidly with age in HIV infected versus uninfected adults. J Clin Exp Neuropsychol 36:356–367. doi:10.1080/13803395.2014.892061

    Article  PubMed  PubMed Central  Google Scholar 

  • Sharma P, Garg S (2010) Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 62:491–502

    Article  CAS  PubMed  Google Scholar 

  • Shugarts S, Benet LZ (2009) The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039–2054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Simioni S, Cavassini M, Annoni JM, Abraham AR, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250. doi:10.1097/QAD.0b013e3283354a7b

    PubMed  Google Scholar 

  • Smith DB, Simmonds P, Bell JE (2014) Brain viral burden, neuroinflammation and neurodegeneration in HAART-treated HIV positive injecting drug users. J Neurovirol 20:28–38. doi:10.1007/s13365-013-0225-3

    Article  CAS  PubMed  Google Scholar 

  • Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25:357–365. doi:10.1097/qad.0b013e32834171f8

    Article  PubMed  PubMed Central  Google Scholar 

  • Streck EL, Scaini G, Rezin GT, Moreira J, Fochesato CM, Romao PR (2008) Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 23:485–492. doi:10.1007/s11011-008-9109-2

    Article  CAS  PubMed  Google Scholar 

  • Sutliff RL, Dikalov S, Weiss D, Parker J, Raidel S, Racine AK, Russ R, Haase CP, Taylor WR, Lewis W (2002) Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circu Physiol 283:H2363–H2370

    Article  CAS  Google Scholar 

  • Tatro ET, Soontornniyomkij B, Letendre SL, Achim CL (2014) Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir. BMC Infect Dis 14:386. doi:10.1186/1471-2334-14-386

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY (2011) Long-term safety from the raltegravir clinical development program. Curr HIV Res 9:40–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Toborek M, Lee YW, Flora G, Pu H, András IE, Wylegala E, Hennig B, Nath A (2005) Mechanisms of the blood–brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25:181–199

    Article  PubMed  Google Scholar 

  • Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343:696–703. doi:10.1124/jpet.112.195701

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322–1326. doi:10.1016/j.bbrc.2004.05.116

    Article  CAS  PubMed  Google Scholar 

  • van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM (2001) Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6:201–229

    PubMed  Google Scholar 

  • van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou X-J, Turner-Foisy ML, Sommadossi J-P, Burger DM, Lange JM, Hoetelmans RM (2000) Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. Aids 14:1187–1194

    Article  PubMed  Google Scholar 

  • Venhoff N, Lebrecht D, Deveaud C, Beauvoit B, Bonnet J, Muller K, Kirschner J, Venhoff AC, Walker UA (2010) Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues. AIDS 24:345–352. doi:10.1097/QAD.0b013e328335cdea

    Article  CAS  PubMed  Google Scholar 

  • Villa G, Solida A, Moro E, Tavolozza M, Antinori A, De Luca A, Murri R, Tamburrini E (1996) Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol 36:125–133

    Article  CAS  PubMed  Google Scholar 

  • Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ (2003) Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids 17:1092–1094

    Article  PubMed  Google Scholar 

  • Vivithanaporn P, Asahchop EL, Acharjee S, Baker GB, Power C (2016) HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. AIDS 30:543–552. doi:10.1097/QAD.0000000000000955

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vourvahis M, Kashuba AD (2007) Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27:888–909. doi:10.1592/phco.27.6.888

    Article  CAS  PubMed  Google Scholar 

  • Wang H, Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598–610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang X, Chai H, Yao Q, Chen C (2007) Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction JAIDS. J Acquir Immune Defic Syndr 44:493–499

    Article  CAS  PubMed  Google Scholar 

  • Wang X, Chai H, Lin PH, Yao Q, Chen C (2009) Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 174:771–781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300. doi:10.1124/jpet.103.049601

    Article  CAS  PubMed  Google Scholar 

  • Watkins CC, Treisman GJ (2015) Cognitive impairment in patients with AIDS—prevalence and severity. HIV AIDS (Auckl) 7:35–47. doi:10.2147/HIV.S39665

    Google Scholar 

  • Wendelken LA, Valcour V (2012) Impact of HIV and aging on neuropsychological function. J Neurovirol 18:256–263. doi:10.1007/s13365-012-0094-1

    Article  PubMed  PubMed Central  Google Scholar 

  • Wise ME, Mistry K, Reid S (2002) Drug points: neuropsychiatric complications of nevirapine treatment. BMJ 324:879

    Article  PubMed  PubMed Central  Google Scholar 

  • Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, de Oliveira AP, Pumpradit W, Shlay JC, El-Sadr W, Price RW, Group ISS (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873. doi:10.1212/WNL.0b013e3181f11bd8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wright PW, Vaida FF, Fernandez RJ, Rutlin J, Price RW, Lee E, Peterson J, Fuchs D, Shimony JS, Robertson KR, Walter R, Meyerhoff DJ, Spudich S, Ances BM (2015) Cerebral white matter integrity during primary HIV infection. AIDS 29:433–442. doi:10.1097/QAD.0000000000000560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu C, Desta Z (2013) In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet 28:362–371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yadav S, Dhawan A, Seth PK, Singh RL, Parmar D (2006) Cytochrome P4503A: evidence for mRNA expression and catalytic activity in rat brain. Mol Cell Biochem 287:91–99. doi:10.1007/s11010-005-9080-8

    Article  CAS  PubMed  Google Scholar 

  • Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52–60. doi:10.1097/01.qai.0000219774.20174.64

    CAS  PubMed  Google Scholar 

  • Zhang X, Cao R, Liu R, Zhao R, Huang Y, Gurley EC, Hylemon PB, Pandak WM, Wang G, Zhang L, Li X, Zhou H (2014a) Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. PLoS One 9:e90856. doi:10.1371/journal.pone.0090856

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhang Y, Song F, Gao Z, Ding W, Qiao L, Yang S, Chen X, Jin R, Chen D (2014b) Long-term exposure of mice to nucleoside analogues disrupts mitochondrial DNA maintenance in cortical neurons. PLoS One 9:e85637. doi:10.1371/journal.pone.0085637

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zheng X, Ouyang H, Liu S, Mata M, Fink DJ, Hao S (2011) TNFalpha is involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats. Brain Behav Immun 25:1668–1676. doi:10.1016/j.bbi.2011.06.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhong D, Lu H, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C (2002) HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22:1560–1566

    Article  CAS  PubMed  Google Scholar 

  • Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO, 64108, USA

    Ankit Shah, Mohitkumar R. Gangwani, Nitish S. Chaudhari, Hari K. Bhat & Anil Kumar

  2. Department of Pathology, School of Medicine, University of Missouri-Kansas City, Kansas City, MO, 64108, USA

    Alexy Glazyrin

Authors
  1. Ankit Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohitkumar R. Gangwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nitish S. Chaudhari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexy Glazyrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hari K. Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anil Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ankit Shah.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shah, A., Gangwani, M.R., Chaudhari, N.S. et al. Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics. Neurotox Res 30, 677–697 (2016). https://doi.org/10.1007/s12640-016-9646-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12640-016-9646-0

Keywords

Search

Navigation